vs
ANGIODYNAMICS INC（ANGO）与泰利福（TFX）财务数据对比。点击上方公司名可切换其他公司
泰利福净利率更高（177.8% vs -8.0%，领先185.7%）。ANGIODYNAMICS INC同比增速更快（9.0% vs -150.5%）。ANGIODYNAMICS INC自由现金流更多（$4.2M vs $-92.9M）。过去两年泰利福的营收复合增速更高（NaN% vs NaN%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
泰利福（Teleflex）总部位于美国宾夕法尼亚州韦恩，是专业医疗设备供应商，产品广泛应用于重症监护、外科手术等各类诊疗场景。公司年营收达24亿美元，在全球40个国家开展业务，员工总数超15000人。经过数年的收并购与业务剥离，公司于2011年完成业务调整，全面聚焦医疗设备制造领域。
ANGO vs TFX — 直观对比
营收规模更大
ANGO
是对方的-0.2倍
$-401.9M
营收增速更快
ANGO
高出159.6%
-150.5%
净利率更高
TFX
高出185.7%
-8.0%
自由现金流更多
ANGO
多$97.2M
$-92.9M
两年增速更快
TFX
近两年复合增速
2.8%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $-401.9M |
| 净利润 | $-6.3M | $-714.3M |
| 毛利率 | 56.4% | — |
| 营业利润率 | -7.7% | — |
| 净利率 | -8.0% | 177.8% |
| 营收同比 | 9.0% | -150.5% |
| 净利润同比 | 40.9% | -422.7% |
| 每股收益（稀释后） | $-0.15 | $-15.85 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGOTFX
| Q4 25 | $79.4M | $-401.9M | ||
| Q3 25 | $75.7M | $913.0M | ||
| Q2 25 | $80.2M | $780.9M | ||
| Q1 25 | $72.0M | $700.7M | ||
| Q4 24 | $72.8M | $795.4M | ||
| Q3 24 | $67.5M | $764.4M | ||
| Q2 24 | $71.0M | $749.7M | ||
| Q1 24 | $75.2M | $737.8M |
净利润ANGOTFX
| Q4 25 | $-6.3M | $-714.3M | ||
| Q3 25 | $-10.9M | $-408.9M | ||
| Q2 25 | $-6.0M | $122.6M | ||
| Q1 25 | $-4.4M | $95.0M | ||
| Q4 24 | $-10.7M | $-136.7M | ||
| Q3 24 | $-12.8M | $111.0M | ||
| Q2 24 | $-13.4M | $80.0M | ||
| Q1 24 | $-187.7M | $15.3M |
毛利率ANGOTFX
| Q4 25 | 56.4% | — | ||
| Q3 25 | 55.3% | 49.5% | ||
| Q2 25 | 52.7% | 55.2% | ||
| Q1 25 | 54.0% | 55.6% | ||
| Q4 24 | 54.8% | 55.3% | ||
| Q3 24 | 54.4% | 56.3% | ||
| Q2 24 | 54.3% | 55.6% | ||
| Q1 24 | 47.7% | 56.4% |
营业利润率ANGOTFX
| Q4 25 | -7.7% | — | ||
| Q3 25 | -14.1% | -44.8% | ||
| Q2 25 | -7.2% | 19.9% | ||
| Q1 25 | -13.9% | 17.9% | ||
| Q4 24 | -15.2% | -13.9% | ||
| Q3 24 | -19.4% | 19.5% | ||
| Q2 24 | -20.4% | 15.6% | ||
| Q1 24 | -265.9% | -0.6% |
净利率ANGOTFX
| Q4 25 | -8.0% | 177.8% | ||
| Q3 25 | -14.4% | -44.8% | ||
| Q2 25 | -7.5% | 15.7% | ||
| Q1 25 | -6.1% | 13.6% | ||
| Q4 24 | -14.7% | -17.2% | ||
| Q3 24 | -19.0% | 14.5% | ||
| Q2 24 | -18.9% | 10.7% | ||
| Q1 24 | -249.7% | 2.1% |
每股收益（稀释后）ANGOTFX
| Q4 25 | $-0.15 | $-15.85 | ||
| Q3 25 | $-0.26 | $-9.24 | ||
| Q2 25 | $-0.15 | $2.77 | ||
| Q1 25 | $-0.11 | $2.07 | ||
| Q4 24 | $-0.26 | $-2.89 | ||
| Q3 24 | $-0.31 | $2.36 | ||
| Q2 24 | $-0.35 | $1.69 | ||
| Q1 24 | $-4.67 | $0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $378.6M |
| 总债务越低越好 | — | $2.6B |
| 股东权益账面价值 | $176.3M | $3.1B |
| 总资产 | $269.7M | $6.9B |
| 负债/权益比越低杠杆越低 | — | 0.85× |
8季度趋势，按日历期对齐
现金及短期投资ANGOTFX
| Q4 25 | $41.6M | $378.6M | ||
| Q3 25 | $38.8M | $354.0M | ||
| Q2 25 | $55.9M | $253.7M | ||
| Q1 25 | $44.8M | $284.1M | ||
| Q4 24 | $54.1M | $290.2M | ||
| Q3 24 | $55.0M | $243.2M | ||
| Q2 24 | $76.1M | $238.6M | ||
| Q1 24 | $78.5M | $237.4M |
总债务ANGOTFX
| Q4 25 | — | $2.6B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益ANGOTFX
| Q4 25 | $176.3M | $3.1B | ||
| Q3 25 | $178.9M | $3.8B | ||
| Q2 25 | $183.0M | $4.2B | ||
| Q1 25 | $185.9M | $4.1B | ||
| Q4 24 | $186.8M | $4.3B | ||
| Q3 24 | $196.6M | $4.5B | ||
| Q2 24 | $205.6M | $4.6B | ||
| Q1 24 | $218.7M | $4.5B |
总资产ANGOTFX
| Q4 25 | $269.7M | $6.9B | ||
| Q3 25 | $265.6M | $7.9B | ||
| Q2 25 | $280.1M | $7.4B | ||
| Q1 25 | $285.4M | $7.2B | ||
| Q4 24 | $291.6M | $7.1B | ||
| Q3 24 | $293.6M | $7.5B | ||
| Q2 24 | $317.7M | $7.4B | ||
| Q1 24 | $324.8M | $7.5B |
负债/权益比ANGOTFX
| Q4 25 | — | 0.85× | ||
| Q3 25 | — | 0.70× | ||
| Q2 25 | — | 0.45× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.39× | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $-92.3M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $-92.9M |
| 自由现金流率自由现金流/营收 | 5.3% | 23.1% |
| 资本支出强度资本支出/营收 | 0.5% | -0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $1.4M |
8季度趋势，按日历期对齐
经营现金流ANGOTFX
| Q4 25 | $4.7M | $-92.3M | ||
| Q3 25 | $-15.9M | $107.8M | ||
| Q2 25 | $18.8M | $7.8M | ||
| Q1 25 | $-13.2M | $73.3M | ||
| Q4 24 | $2.5M | $202.6M | ||
| Q3 24 | $-18.3M | $231.1M | ||
| Q2 24 | $5.0M | $91.7M | ||
| Q1 24 | $-12.5M | $112.8M |
自由现金流ANGOTFX
| Q4 25 | $4.2M | $-92.9M | ||
| Q3 25 | $-16.6M | $77.8M | ||
| Q2 25 | $18.0M | $-26.8M | ||
| Q1 25 | $-15.0M | $43.3M | ||
| Q4 24 | $1.7M | $170.6M | ||
| Q3 24 | $-19.3M | $209.9M | ||
| Q2 24 | $4.4M | $56.9M | ||
| Q1 24 | $-13.1M | $74.4M |
自由现金流率ANGOTFX
| Q4 25 | 5.3% | 23.1% | ||
| Q3 25 | -22.0% | 8.5% | ||
| Q2 25 | 22.5% | -3.4% | ||
| Q1 25 | -20.8% | 6.2% | ||
| Q4 24 | 2.3% | 21.4% | ||
| Q3 24 | -28.7% | 27.5% | ||
| Q2 24 | 6.2% | 7.6% | ||
| Q1 24 | -17.5% | 10.1% |
资本支出强度ANGOTFX
| Q4 25 | 0.5% | -0.2% | ||
| Q3 25 | 1.0% | 3.3% | ||
| Q2 25 | 1.0% | 4.4% | ||
| Q1 25 | 2.5% | 4.3% | ||
| Q4 24 | 1.1% | 4.0% | ||
| Q3 24 | 1.6% | 2.8% | ||
| Q2 24 | 0.8% | 4.6% | ||
| Q1 24 | 0.8% | 5.2% |
现金转化率ANGOTFX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 0.77× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.08× | ||
| Q2 24 | — | 1.15× | ||
| Q1 24 | — | 7.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
TFX
暂无分部数据
